Jun 7, 2026
May 27, 2026
Cardiosense Receives FDA De Novo Classification for Novel Cardiac Technology Designed to Improve Care for Patients with Heart Failure
May 21, 2026
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
May 20, 2026
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001
May 14, 2026
Nyra Medical to Highlight First-in-Human Clinical Insights Through Three Presentations at EuroPCR
Apr 7, 2026